Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells
Rebecca T. Veenhuis, … , Michael A. Chattergoon, Andrea L. Cox
Rebecca T. Veenhuis, … , Michael A. Chattergoon, Andrea L. Cox
Published October 30, 2017
Citation Information: J Clin Invest. 2017;127(12):4352-4364. https://doi.org/10.1172/JCI95375.
View: Text | PDF
Research Article AIDS/HIV Inflammation

HIV-antibody complexes enhance production of type I interferon by plasmacytoid dendritic cells

  • Text
  • PDF
Abstract

Type I IFN production is essential for innate control of acute viral infection; however, prolonged high-level IFN production is associated with chronic immune activation in HIV-infected individuals. Although plasmacytoid DCs (pDCs) are a primary source of IFN, the mechanisms that regulate IFN levels following the acute phase are unknown. We hypothesized that HIV-specific Ab responses regulate late IFN production. We evaluated the mechanism through which HIV-activated pDCs produce IFN as well as how both monoclonal HIV-specific Abs and Abs produced in natural HIV infection modulated normal pDC sensing of HIV. We found that HIV-induced IFN production required TLR7 signaling, receptor-mediated entry, fusion, and viral uncoating, but not endocytosis or HIV life cycle stages after uncoating. Abs directed against the HIV envelope that do not interfere with CD4 binding markedly enhanced the IFN response, irrespective of their ability to neutralize CD4+ T cell infection. Ab-mediated enhancement of IFN production required Fc γ receptor engagement, bypassed fusion, and initiated signaling through both TLR7 and TLR9, which was not utilized in the absence of Ab. Polyclonal Abs isolated from HIV-infected subjects also enhanced pDC production of IFN in response to HIV. Our data provide an explanation for high levels of IFN production and immune activation in chronic HIV infection.

Authors

Rebecca T. Veenhuis, Zachary T. Freeman, Jack Korleski, Laura K. Cohen, Guido Massaccesi, Alessandra Tomasi, Austin W. Boesch, Margaret E. Ackerman, Joseph B. Margolick, Joel N. Blankson, Michael A. Chattergoon, Andrea L. Cox

×

Figure 3

HIV Ab specificity regulates type I IFN production by pDCs.

Options: View larger image (or click on image) Download as PowerPoint
HIV Ab specificity regulates type I IFN production by pDCs.
HIVBaL was c...
HIVBaL was cultured with (A) anti-gp120 Abs that interfere with CD4 binding (B12, PG9, PG16, and VRC01) or with an anti-gp120 Ab that does not interfere with CD4-binding (2G12), (B) VRC01 FcγR-binding variants that either enhanced Fc binding to the designated FcγR or prevented all FcγR binding, or (C) anti-gp41 Abs for 1 to 2 hours, which were then added to pDCs. Supernatants were harvested after 15 hours and assessed for IFN-α protein production (A–C) (n = 4). (D) HIVBaL was cultured with 4E10 for 1 to 2 hours and then added to pDCs. Supernatants were harvested and assessed for IFN-α protein production at 1, 5, 12, and 16 hours. Data from 1 representative experiment completed in triplicate. Each data point indicates the average IFN-α production from 1 donor’s pDCs tested in at least duplicate and normalized to media conditions. Error bars and gray boxes represent SEM and the mean, respectively. Conditions were compared using 1-way ANOVA with Dunnett’s multiple comparisons test. *P < 0.05.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts